A B S T R A C T Intact sheep antidigoxin antibodies and their Fab fragments have both been found to exert profound effects on digoxin pharmacokinetics in [3H]digoxin-treated dogs. Both classes of molecule remove digoxin from the extravascular space and sequester it in the circulation in protein-bound form, a form in which the digoxin is presumably inactive. These two classes of molecule differ, however, in that the intact antibody molecules interfere with digoxin excretion, thereby promoting the retention of the glycoside; this retained digoxin is eventually released in free, active form when the administered antibody is metabolically degraded. In contrast, urinary excretion of digoxin continues in Fab-treated dogs, with significant quantities of digoxin being excreted promptly in the urine in complex with Fab fragments. These differences in urinary excretion, together with the probable decreased immunogenicity of sheep antidigoxin Fab fragments, suggest that such fragments possess potential advantages over intact antibody molecules for use in the therapy of life-threatening digoxin intoxication in man.
INTRODUCTION
Experimental animals immunized with synthetic digoxin-protein conjugates form antibodies with speciThese studies have been presented in part to the Scientific Session of the American Heart Association at Atlantic City, N. J., 11 November 1973 (1) . Dr Received for publication 10 February 1976 and in revised form 21 October 1976. ficity for the unconjugated digitalis glycoside, digoxin (2) . In vitro, antibodies to digoxin or to other cardiac glycosides are capable of removing these glycosides from mammalian cells (3, 4) and of preventing or of reversing many of the pharmacologic and toxic effects of the glycosides on such cells (3) (4) (5) (6) (7) (8) (9) (10) . In vivo, antidigoxin antibodies are capable of preventing or of reversing lethal digoxin intoxication in experimental animals (11) (12) (13) . These properties of digoxin-specific antibodies have prompted consideration of the possibility that these antisera might be of clinical value in the reversal of severe digoxin intoxication in man (5, 7, 9, 12, 13) .
Two major problems, however, might be anticipated if heterologous antidigoxin serum were to be administered in human subjects. One problem is the danger of immunological reactions to foreign serum proteins, as manifested clinically by anaphylaxis or serum sickness. The second problem arises from the fact that the manner in which the administration of antibodies might alter the metabolism and excretion of digoxin has not been established. It is known, however, that digoxin-binding antibodies in the sera of actively immunized rabbits slow the excretion of digoxin and markedly prolong its biologic half-life (14) ; therefore, if the administration of heterologous antibody had a similar effect, one might anticipate that the eventual immunologic elimination of the foreign protein could be relatively rapid and be accompanied by release of bound glycoside in its free, active, and potentially toxic form (7, 9) .
In the hope of minimizing these problems, digoxinbinding Fab fragments of antidigoxin antibodies have been purified. These Fab fragments are smaller (50,000 daltons) than intact IgG antibodies (160,000 daltons). Each Fab fragment contains one digoxin-binding site in contrast to the two binding sites present in intact IgG, but Fab fragnents possess biologic activity com-parable to that of equivalent concentrations of intact antibodies (10, 15) . Since (18) , Fab fragments are excreted, at least in part, in the urine (17, 18) . It has therefore been suggested that, if the antigen-binding sites of such excreted antidigoxin Fab fragments remain intact, these fragments might be capable of binding digoxin in vivo and then, in contrast to intact antidigoxin antibody, of permitting or promoting the relatively prompt urinary excretion of digoxin, thereby minimizing the potential hazards connected with late release of bound, retained digoxin from intact heterologous antiglycoside antibody molecules (5, 7, 9, 15) .
It is the purpose of this report to present evidence that both sheep antidigoxin antibodies and their Fab fragments exert profound effects on the pharmacokinetics of digoxin in dogs.
METHODS
Antisera. Digoxin was conjugated to bovine serum albumin (BSA)' by the periodate oxidation method (19) as described in detail elsewhere (2, 20) . The synthetic BSAdigoxin was made up to a final concentration of 1 mg/ml in complete Freund's adjuvant mixture (20) and repetitively injected intramuscularly, 0.5 ml at each of two sites, into adult sheep, usually at 2-4 wk intervals. Control antiserum was obtained from a sheep immunized in a similar manner with a 1-methyladenosine-BSA conjugate also prepared by the periodate oxidation method (19) .
Sheep gamma globulin (SGG; fraction II, Miles Laboratories, Inc., Elkhart, Ind.) was purified by chromatography on DEAE-cellulose (standard grade; Schleicher & Schuell, Inc., Keene, N. H.) in 0.02 M phosphate buffer, pH 7.0, as previously described (3) . White New Zealand rabbits, weighing 2-3 kg, were immunized by the injection of SGG, 1 mg/ml in complete Freund's adjuvant mixture, according to a schedule described previously (11) . Sera Immunoadsorbents. CGG was coupled to agarose by the cyanogen bromide method (22, 23) . Bromoacetyl cellulose was prepared according to the method of Robbins et al. (24) . Ouabain-ribonuclease was prepared and coupled to bromoacetyl cellulose as previously described (13) .
'Abbreviations used in this paper: BSA, bovine serum albumin; SGG, sheep gamma globulin; CGG, canine gamma globulin.
Preparation of antidigoxin Fab fragments. A globulin fraction of sheep antidigoxin serum was prepared by an ammonium sulfate precipitation method (25) as follows: to 200 ml antiserum, 100 ml saturated (NH4)2SO4 was added with stirring; the suspension was adjusted to pH 7.8 with 5 N NaOH and centrifuged for 30 min at 500 g at room temperature. The globulin precipitate was redissolved in 100 ml 0.15 M NaCl, 0.1 M sodium phosphate, pH 7.5, and dialyzed overnight against 2,000 ml of the same buffer.
The globulin fraction was digested with papain according to the method of Nisonoff (26) in a freshly made reaction mixture containing 0.002 M sodium EDTA and 0.01 M L-cysteine in 0.1 M sodium phosphate buffer, pH 7.5. Papain (twice crystallized, Worthington Biochemical Corp., Freehold, N. J.) was added dropwise with stirring to a protein concentration 1/100kh that of the globulin in the final reaction mixture. After a 3-h incubation in a stoppered flask with shaking at 37°C, the mixture was placed in an ice water bath, and iodoacetic acid in 0.1 M Na2HPO4 was added to a final concentration of 15 mM. After 2.5 h at 0°C, the reaction mixture was dialyzed overnight at 4°C against 4 liters of 0.15 M NaCl, 0.04 M sodium phosphate, pH 7.4, and further purified in one of two ways. For studies in three dogs in which large quantities of antidigoxin Fab fragments were required, the mixture was subjected to gel filtration on Sephadex G-150 (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.); the first IgG-containing peak eluted from this column was discarded and the second, Fab-containing peak was pooled and administered as "partially purified antidigoxin Fab fragments". For all other studies, the papain-digested globulin mixture was added in eight equal portions to 750-mg aliquots of the bromoacetyl celluloseribonuclease-ouabain immunoadsorbent (an immunoadsorbent previously shown to be capable of adsorbing antidigoxin antibodies and their Fab fragments [10, 13] ) and stirred for 4 h at 40C and for 30 min at 37°C. The suspension was centrifuged at 4°C for 10 min at 10,000g. After decanting and discarding the supernatant solution, the immunoadsorbent was washed three times with chilled 0.15 M NaCl, 0.01 M potassium phosphate, pH 7.4, by centrifuging 10 min at 10,000 g at 4°C. Fab fragments of antibody were eluted as previously described (13) with three successive additions (15, 10 , and 10 ml) of 25 mM ouabain (ouabain octahydrate, Sigma Chemical Co., St. Louis, Mo.), stirring 30 min at 370C and again centrifuging 10 min at 10,000 g at 4°C. The eluates from all portions were pooled, lyophilized, and taken up in distilled water to a 100-ml vol (much of the ouabain did not dissolve, and a substantial removal of free ouabain was achieved at this step). To (Table I) . Average intrinsic association constants were also calculated from the observed data, using methods outlined by Eisen (28) .
Radioiodination of SGG and antidigoxin Fab fragments. SGG and antidigoxin Fab fragments, prepared as described above, were radiolabeled with 125I by the lactoperoxidase method (29, 30) . To 100 ,ul of 0.05 M phosphate buffer, pH 7.5, the following reagents were added (with mixing after each addition) in the following order: 5 or 10 ul SGG or Fab (1 pig/pAl in buffer); 5 i.l bovine lactoperoxidase (B grade, Calbiochem, San Diego, Calif.; 1 p.g/.il in buffer); 2 mCi 125I (Nal, in NaOH; carrier-free; Cambridge Nuclear Corp., Cambridge, Mass.); and, 5 ul hydrogen peroxide (6 ng/,u in buffer). After a 5-min incubation at room temperature, 0.5 ml buffer was added, and the reaction mixture was passed over a 1.0 x 20-cm column of Sephadex G-50 (Pharmacia Fine Chemicals), over which had been previously passed 1 ml 2% BSA in buffer, followed by 30 ml protein-free buffer. The first 125I-containing material eluted from this column was frozen and stored at -200C until use.
Preparation of digoxin for pharmacokinetic studies.
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Effects of Digoxin-Specific Antibodies and Fab Fragments
(60-180 mg) was administered as necessary to keep the animals anesthetized during the initial 6 h of the study, during which time a catheter was kept in place in the urinary bladder and an intravenous infusion of 300 ml 0.9%o NaCl or Ringer's lactate solution was administered. After insertion of the catheter and institution of the infusion, [3H]digoxin in a 0.02-mg/kg body weight dosage, prepared as described above, was administered intravenously over a 10-min period. 2 h later, one group of animals received freshly centrifuged (5,000 g, 15 min, 40C) whole sheep antidigoxin serum (25 ml, except dog WS-1, which received 30 ml) and a second group of dogs received purified antidigoxin Fab fragments (17-43 mg in 10-60 ml 0.85% NaCl), both administered intravenously over a 10-min period. Details concerning these two groups of dogs and the antiserum or Fab fragments which they received are presented in Table I mined simultaneously as follows: to each of four tubes, 0.5 ml of a 1:5 dilution of test serum or of a 1:21 dilution of test urine was added. To two tubes, 0.25 ml of dextrancoated charcoal (2% dextran T-40, 20% charcoal in Trisbuffered saline, pH 7.4) was added, and to two control tubes, was added 0.25 ml buffered albumin. After mixing, the tubes were centrifuged at 900 g for 1 h at 4°C. The supernatant solution was decanted into scintillation vials containing 15 ml of a toluene-Triton X-100 scintillation mixture (11) . The vials were heated at 80°C for 30 min, allowed to cool, and then counted in a Tri-Carb liquid scintillation counter (Packard Instrument Co., Inc., Downers Grove, Ill.); internal standards of [3H]digoxin were added to each sample, and the samples were recounted to correct for quenching. Utilizing the known specific activity of the administered [3H]digoxin, total digoxin concentrations in test serum and urine specimens were determined from the amounts of digoxin present in control tubes containing buffered albumin without charcoal; protein-bound [3H]digoxin was then expressed as the fraction of digoxin present in the supernatent of the tubes to which dextran-coated charcoal had been added. Total and protein-bound concentrations were then plotted on a logarithmic scale (ordinate) against time on a linear scale (abscissa).
Since the dextran-coated charcoal method measures [3H]digoxin bound to other molecules as well as to immunoglobulin molecules, the double-antibody method was used to determine the amount of digoxin bound to immunoglobulins or to Fab fragments in some serum and urine specimens (14, 32) . 200 jul of test serum was added to duplicate tubes containing 1.0 ml of a 1:10 dilution of CGG-absorbed anti-SGG serum, or 200 1.l of a 1:10 dilution of urine was added in duplicate to 1.0 ml of a 1:32 dilution of unabsorbed anti-SGG serum. In duplicate control tubes, 200 ,ul of test serum or of the 1:10 dilution of test urine was added to 1.0 ml of buffered albumin. After mixing, the tubes were placed in a 37°C water bath for 1 h, refrigerated at 4°C for 5-6 days, and centrifuged for 1 h at 4°C and 1,100 g. The precipitates were washed three times with chilled 0.85% NaCl, digested in 0.5 ml Soluene (Packard Instrument Co. Inc.), transferred to scintillation vials with the aid of two 5-ml portions of Dimilume (Packard Instrument Co. Inc.) and counted in the liquid scintillation spectrometer, using the subsequent addition of [3H]digoxin internal standards to correct for quenching. In each instance, 1 ml of supernatant solution was counted in 10 ml Dimilume in a similar manner. The remainder of the supernatant solution was assessed for residual antibody-bound or Fab-bound radioactivity by the addition of further anti-SGG antiserum, but in no instance was there precipitation of significant radioactivity. Immunoglobulin-bound or Fab-bound digoxin was calculated as the percent of the recovered serum or urinary radioactivity detected in the original precipitate.
Radioimmunoassay of SGG and Fab fragments. A globulin fraction of CGG-absorbed anti-SGG serum was prepared by the sodium sulfate method of Kekwick (33) and Strauss et al. (34) and coupled to bromoacetyl cellulose by the method of Robbins et al. (24) . Solid-phase radioimmunoassays were carried out in 0.35% BSA in pH 7.4, Trisbuffered saline (11) as follows: to duplicate tubes to be used in the construction of a standard curve were added 1.0-ml portions of buffer containing 0-1,000 ng unlabeled SGG or Fab and 100 ,ul of various dilutions (undiluted to 1:1,000) of normal canine serum or urine; corresponding 100-AlI volumes of the same dilutions of the serum or urine specimens being analyzed were added in duplicate to 1.0 ml buffer. To all tubes, 50 IlI (0.02 ,uCi) 125I-labeled SGG or Fab was added followed, after mixing, by 0.5 ml of a suspension containing sufficient bromoacetyl cellulose-anti-SGG to bind 40%o of the added radioactivity in the absence of unlabeled antigen. After a 30-min incubation in a 37°C water bath, the tubes were centrifuged for 10 min at 6,200 g and 4°C; after decantation of the supermatant fluid, both precipitate and supernatant radioactivity were counted in an Auto-Gamma Spectrometer (Packard Instrument Co. Inc. h-uman serum albumin in pH 7.4 Tris-buffered saline were mixed with varying amounts (6.5-52 ng) of [3H]digoxin (50 ,ul volume) of the same specific activity (0.39 ,uCi/,ug) which had been administered to the dog. After a 10-min incubation at room temperature, 0.25 ml dextran-coated charcoal was added, and the protein-bound digoxin was determined as described above in the section, Digoxin determinations. The maximal amount of digoxin bound under these conditions was considered to represent the total digoxin-binding capacity ofthe L1O0-pl serum dilution assayed. 348 Butler, Schmidt, Smith, Haber, Raynor, and Demartini
Results were expressed in nanograms digoxin per milliliter canine serum. Density gradient ultracentrifugation. 1 ml of serum or urine, diluted 1-3 in 10%o sucrose, was layered onto an 11.8 or 12.4 ml linear gradient of 10-40% sucrose and centrifuged for 18 liquid scintillation mixture (11), using the liquid scintillation spectrometer.
Detection of antibodies to SGG or sheep Fab fragments in dog sera. Canine sera were assessed for the presence of antibodies to SGG or to sheep Fab fragments by measuring the ability of these sera to agglutinate human group 0 erythrocytes, coated with SGG or with sheep Fab fragments by the bisdiazotized benzidine passive hemagglutination method, performed as previously described (35) .
RESULTS
In Fig. la [3H]digoxin, which had remained near the top of the gradient in serum obtained from this animal before antibody administration, sedimented with the 7S immunoglobulin-containing fraction in serum specimens obtained 1 and 11 days after antibody administration; a similar result was observed with serum obtained from dog WS-8 4 h after the antibody was given. (b) A more direct demonstration that most of the [3H]digoxin, which was protein-bound as assessed by the coated charcoal method, was indeed bound to SGG, was obtained by demonstrating that the labeled glycoside coprecipitated with SGG when CGG-absorbed anti-SGG serum was added to representative canine serum specimens (Table II) .
Serum digoxin concentrations remained elevated for several days after antibody administration but then, in most animals, began to decrease sharply after about 6 or 7 days (Figs. lb, 3a) . For example, in dog WS-8, a 100-fold decrease in serum digoxin from 112 to 1.1 ng/ml, occurred between days 6 and 9 (Fig. 3a) ; similarly, a 50-fold decrease from 70 to 1.4 (Figs. 3b,  4a) ; in specimens obtained from two of these dogs, the total digoxin-binding capacity of the dog serum was also determined at various time intervals (Fig.  3c) . The serum concentrations of SGG began to decrease immediately after the 1st day (Figs. 3b, 4a ) but, as can be seen in Fig. 3c, (Figs. 3, ia) . In dog (Fig. 3 ) and in two of the four dogs depicted in Fig. 4a , it was noteworthy that sharp decreases in SGG concentration (and, (Figs. 2b, 3d) . In these animals, presumably as a result of the binding of digoxin by antibody, urinary digoxin excretion rates decreased to negligible values immediately following antibody administration. In most animals, there was a slight increase in the percentage of urinary digoxin which appeared to be (Table III) . The urinary digoxin excretion rate remained low for several days and then, at about the time at which the serum concentration began to decrease rapidly, an increase in urinary digoxin excretion, mainly in free nonprotein-bound form, was observed in most instances (Figs. 2b, 3d ). Six dogs were studied extensively after having been given purified sheep antidigoxin Fab fragments (1.4- protein-bound [3H]digoxin was Fab-bound, as shown by its coprecipitation with Fab fragments when CGG-absorbed anti-SGG serum was added to representative canine serum specimens (Table II) and by its sedimentation in the 3.5S fraction in sucrose density gradient ultracentrifugation. Unlike dogs receiving intact antidigoxin antibodies, in whose sera digoxin concentrations initially decreased slowly, serum digoxin concentrations fell rather rapidly over the next 18 h.
Serum immunoreactive sheep Fab fragment concentrations were measured serially in six Fab-treated dogs (Figs. 4b, 5b) . Unlike serum SGG concentrations which initially decreased slowly in dogs receiving intact antibody (Figs. 3b, 4a) , serum immunoreactive Fab concentrations fell rather rapidly over the first 24 h of study (Figs. 4b, 5b) (Figs. lc, 5a) , together with the slower disappearance rate of immunoreactive Fab after the 1st day, suggested that intact antibody molecules or fragments of sizes larger than Fab fragments might have been present in the circulation of these Fab-treated dogs. In the case of dog Fab-10, sucrose density gradient ultracentrifugation of serum obtained as soon as 4 h after Fab administration revealed that, in contrast to a specimen obtained 1 h after Fab administration, much of the [3H]digoxin was in the 7S IgG portion of the gradient. Polyacrylamide disk gel electrophoresis in sodium dodecyl sulfate was then performed retrospectively on some of the Fab preparations used in this study and revealed, in most instances, faint traces of a component with a mobility identical to that of intact sheep IgG. Efforts are now being made to isolate Fab preparations which are free of intact immunoglobulin molecules.
In the serum of dog Fab-10, the disappearance rate of the digoxin-binding capacity was studied and found to parallel closely the serum disappearance rate of immunoreactive Fab (Figs. 5b, c) (Table III) . Despite the fact that a significant amount of the urinary digoxin was excreted in complex with Fab fragments, the urinary excretion of digoxin during the 22-h period after Fab administration (Table IV) significantly greater (52.4%) in three dogs which were given single large doses of partially purified antidigoxin Fab fragments of 22.1-22.6 mg/kg (Table  IV) , doses comparable in digoxin-binding capacity with the doses of intact antibodies administered to the antibody-treated group (Table I) . It may be noted, however, that 42-80%o of the digoxin excreted during hours 2 through 24 by the three Fab-treated groups was in protein-bound form (Table IV) .
Using the bisdiazotized benzidine hemagglutination technique, no antibodies to SGG or to sheep Fab fragments could be detected in the last serum specimens obtained from five dogs receiving antidigoxin serum and from five dogs receiving purified antidigoxin Fab fragments.
DISCUSSION
Both intact antidigoxin antibodies and their Fab fragments produced prompt and striking increases in the serum concentrations of digoxin and of its proteinbound fraction. Since it has been previously demonstrated that antidigoxin antibodies and their Fab fragments are capable of reversing the pharmacologic and toxic effects of digoxin (3-7, 9, 10, 12, 13, 15, 39) , it is presumed that the circulating antibody-bound and Fab-bound digoxin is pharmacologically inactive. In the course of these prior studies of the pharmacologic effects of antidigoxin antibodies, it has been shown that these antibodies are capable of removing digoxin from mammalian cells (3, 4) . Thus, the striking rises in serum digoxin concentrations in both the antibody-treated and the Fab-treated dogs are most consistent with the removal of digoxin from an extravascular compartment or compartments. Since canine tissues were not analyzed in the current study, the extravascular sources of digoxin cannot be identified. It is of interest, however, that tissue digoxin appears to consist of intracellular and cell membranebound components (4, 40) and that antidigoxin antibodies remove intracellular glycoside from human erythrocytes more rapidly than they remove the glycoside from cell membrane-binding sites (4) . In this connection, it is possible that the prolonged phase of removal of digoxin from an extravascular compartment during hours 6-24 in the antibody-treated dogs is contributed to by slow dissociation of digoxin from specific binding sites on cell membranes, analogous to the slow dissociation of digoxin from such sites on human erythrocyte membranes with consequent slow sequestration by antidigoxin antibodies (4) .
Serum digoxin concentrations remained elevated for 5-7 days in most antibody-treated dogs (Figs.  1, 3) ; then, as the heterologous sheep antibodies were eliminated, 50-to 100-fold decreases in serum digoxin occurred within 48-72 h, presumably reflecting both tissue uptake of released digoxin and its urinary excretion in unbound forn (Figs. 2, 3 ; Table  356 Butler, Schmidt, Smith, Haber, Raynor, and Demartini IV). In contrast with the protracted elevations in the antibody-treated group, serum digoxin concentrations began to fall within 4-10 h after Fab administration; this decrease presumably reflects urinary excretion of digoxin and catabolic degradation of Fab fragments. The mean maximal rise in serum digoxin in 13 dogs treated with various doses of Fab fragments was 8.2-fold in contrast with the 50.5-fold rise caused by intact antibodies. The basis for this difference has not been established in the current study. Since the maximal rise was only 6.1-fold in the three dogs given doses of Fab fragments comparable with antibody doses, it does not appear that dosage differences were responsible. Continued urinary digoxin excretion and rapid Fab catabolism may have been factors in the Fab-treated dogs. Another possible contributory factor may have been a greater volume of distribution for Fab fragments than for the larger intact antibody molecules but, at this time, there is no direct evidence to support this possibility.
Although urinary recovery of administered [3H]digoxin was not complete, it can be seen that urinary excretion ofdigoxin was markedly delayed in antibodytreated dogs, while continuing in the Fab-treated animals (Table IV) . During the 22-h period after antibody administration (hours 2-24 of study), only 6.9%o of the recovered digoxin was found in the urine of antibody-treated dogs, in contrast with 38.4% in the control group and 41.3-52.4% in the three Fabtreated groups. During the period after more than 96 h had elapsed, 58.2% of the recovered digoxin was found in the urine of the antibody-treated animals in contrast with 2.3-7.4% in the control and Fabtreated groups.
It seems likely that the protracted sequestration of digoxin in antibody-bound form in plasma retards its urinary excretion by the antibody-treated dogs. Since body stores of digoxin are initially maintained at the level present before antibody administration, the clinical use of intact antibody to reverse digoxin intoxication could conceivably be accompanied by the retention of potentially toxic digoxin stores within the body. If large stores of the glycoside were to be abruptly released from antibody during the rapid immunologic degradation of heterologous sheep immunoglobulin, toxic complications caused by the released digoxin could conceivably ensue several days after antibody administration. Inasmuch as excretion of digoxin by Fab-treated dogs continued, it was concluded that the use of Fab fragments would not only reverse digoxin intoxication, but would also permit the prompt excretion of toxic body stores of the drug, much of it in protein-bound, and presumably inactive, form.
In dogs receiving the smaller doses of antidigoxin No dog in this study developed overt serum sickness, but the presence of serum sickness in this species could have escaped our attention. Furthermore, we did not detect anti-SGG or anti-Fab antibodies in the sera of these dogs. Thus, no conclusions can be drawn from this study conceruing the relative immunogenicity of sheep serum (containing intact antibodies) and of purified Fab fragments. However, in our experience2 and that of others,3 Fab fragments are less immunogenic than intact immunoglobulin molecules in eliciting antibody formation in experimental animals. Certainly, in man, the administration of substantial quantities of heterologous serum would be accompanied by an appreciable incidence of serum sickness (41) , whereas the use of proteolytic fragments of purified immunoglobulins reduces the risk of serum sickness (42) .
The fact that digoxin is excreted promptly, much of it in protein-bound form, in Fab-treated dogs together with the probable lesser immunogenicity of Fab fragments suggest that antidigoxin Fab fragments have theoretical advantages over intact antibody molecules in the immunologic treatment of severe, potentially lethal, digoxin intoxication in man (43) (44) (45) (46) which does not respond to currently available forms of antiarrhythmic, symptomatic, and supportive therapy (45) . One patient with advanced digoxin intoxication has recently been successfully treated with antidigoxin Fab fragments; digoxin pharmacokinetics in this patient were similar to digoxin pharmacokinetics in dogs given Fab fragments in the current study (47 
